SOAN - AngioSoma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0045
+0.0001 (+2.27%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.0044
Open0.0044
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0039 - 0.0051
52 Week Range0.0020 - 0.0400
Volume1,411,000
Avg. Volume5,073,696
Market Cap579,618
Beta (3Y Monthly)-3.48
PE Ratio (TTM)N/A
EPS (TTM)-0.0090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    AngioSoma Confirms Status of Voting Control

    Houston, TX , Aug. 20, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has filed an amendment to its Form 10-K for the fiscal year ended.

  • GlobeNewswire

    AngioSoma to Advertise in U.S. Airports

    HOUSTON, TX, April 22, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN), a leading developer of dietary supplements, is pleased to announce a one-year advertising.

  • GlobeNewswire

    AngioSoma Launches E-Commerce Website

    HOUSTON, TX, April 15, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN), a leading developer of dietary supplements and biotechnology research and development company,.

  • GlobeNewswire

    Diabetes Relief's Programs Can Reduce Costs to Insurance Payers

    HOUSTON, TEXAS, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (SOAN) is concerned that economic costs of diabetes in the USA were $327 BILLION in 2017, as reported by the American Diabetes Association. Of that total, $98 BILLION was spent on diabetic hospital admissions and $10.9 BILLION on diabetic neuropathy alone. Diabetes Relief’s patients report marked improvement in neuropathy as well as fewer hospitalizations, and testimonials are available at www.diabetesrelief.com.

  • GlobeNewswire

    AngioSoma Announces New Facility in San Antonio for Diabetes Relief

    HOUSTON, TX, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (SOAN) announces that Diabetes Relief LLC has licensed a new facility in San Antonio, Texas for its patented treatment, which is about to open. “Diabetes Relief is proud of this facility, which is an important cog in our expansion wheel as we move further west into Texas,” said Dr. Stanley T. Lewis, Chief Medical Officer.

  • GlobeNewswire

    AngioSoma Announces Accomplishments of Diabetes Relief

    Houston, TX, March 06, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief.

  • eQuine Holdings Discloses 8% Stake In AngioSoma (SOAN)
    PR Newswire

    eQuine Holdings Discloses 8% Stake In AngioSoma (SOAN)

    DALLAS , Dec. 28, 2018 /PRNewswire/ -- eQuine Holdings, a Class II Multi-Family Office, has disclosed an eight percent (8%) equity stake in AngioSoma (OTC-PINK:SOAN). On December 17, 2018 AngioSoma announced ...

  • GlobeNewswire

    AngioSoma Announces Acquisition of Diabetes Relief

    Houston, TX, Dec. 14, 2018 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100%.

  • GlobeNewswire

    AngioSoma Creates New Partnership Opportunity

    Peripheral Artery Disease Device Manufacturer Targeted for Joint Venture HOUSTON, Nov. 13, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research.

  • GlobeNewswire

    AngioSoma Launching Holiday Awareness Campaign

    Heart Health Focused Campaign Set to Kick Off December 1st, 2018 HOUSTON, TX, Nov. 12, 2018 -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology research and.

  • GlobeNewswire

    AngioSoma Committed to Expanding Cosmeceutical Future

    New Industry Data and Product Roadmap Align for Optimistic Outlook HOUSTON, Nov. 08, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and.